ENvue Medical, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-12, effective September 1, 2026. The transaction was approved by the board and stockholders on August 14, 2026, and implemented via a Certificate of Amendment filed with Delaware on August 28, 2026. Outstanding shares will decrease from approximately 11,084,616 to roughly 923,718, with fractional shares rounded up to the nearest whole share rather than cashed out. The trading symbol remains FEED on Nasdaq, though a new CUSIP number applies. ENvue Medical is a medical technology company specializing in non-invasive enteral care solutions and acoustic-based therapeutic devices.

ENvue Medical entered into a committed equity facility allowing it to sell up to $50 million of common stock at 90% of the three-day VWAP, with proceeds earmarked for Series X Preferred Stock redemption and working capital. Simultaneously, the company amended its July 2025 Series H Preferred Stock purchase agreement to increase total additional investment rights to a $59 million stated value, contingent on shareholder approval. The investor must exercise at least $10 million within twelve months of approval, with monthly minimums of approximately $833,333. ENvue Medical operates in the healthcare technology sector, providing practice management software for medical groups.

On July 14, 2026, ENvue Medical, Inc. announced a series of board of directors changes, including the voluntary resignations of David Johnson and Nino Pionati. The Board appointed Zvi Joseph and Lior Buchman to fill the vacancies, with Joseph and Buchman both serving on the Audit Committee. Zeev Rotstein, M.D., an existing board member, was appointed as the new Chairman of the Board. ENvue Medical, Inc. operates in the medical technology industry and develops medical devices for skin and tissue engineering.

ENvue Medical, Inc. received a Nasdaq Staff Determination Letter on July 10, 2026, notifying the company of its failure to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. Due to a prior 1-for-10 reverse stock split on August 12, 2025, the company is ineligible for a 180-day compliance period. The company intends to appeal the determination via a hearing before the Panel. ENvue Medical, Inc. operates in the medical technology industry and develops medical devices for skin-related conditions.